Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Impact of an HIV Care Coordination Program on Durable Viral Suppression.

Robertson MM, Penrose K, Irvine MK, Robbins RS, Kulkarni S, Braunstein SL, Waldron L, Harriman G, Nash D.

J Acquir Immune Defic Syndr. 2019 Jan 1;80(1):46-55. doi: 10.1097/QAI.0000000000001877.

PMID:
30299346
2.

Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma.

Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, Fujiwara N, Leong V, Houde VP, Anagnostopoulos AE, Wang A, Broadfield LA, Ford RJ, Foster RA, Bates J, Sun H, Wang T, Liu H, Ray AS, Saha AK, Greenwood J, Bhat S, Harriman G, Miao W, Rocnik JL, Westlin WF, Muti P, Tsakiridis T, Harwood HJ Jr, Kapeller R, Hoshida Y, Tanabe KK, Steinberg GR, Fuchs BC.

Cell Metab. 2019 Jan 8;29(1):174-182.e5. doi: 10.1016/j.cmet.2018.08.020. Epub 2018 Sep 20.

PMID:
30244972
3.

Redefining Prevention and Care: A Status-Neutral Approach to HIV.

Myers JE, Braunstein SL, Xia Q, Scanlin K, Edelstein Z, Harriman G, Tsoi B, Andaluz A, Yu E, Daskalakis D.

Open Forum Infect Dis. 2018 May 2;5(6):ofy097. doi: 10.1093/ofid/ofy097. eCollection 2018 Jun.

4.

Acetyl-coenzyme A carboxylase inhibition reduces de novo lipogenesis in overweight male subjects: A randomized, double-blind, crossover study.

Stiede K, Miao W, Blanchette HS, Beysen C, Harriman G, Harwood HJ Jr, Kelley H, Kapeller R, Schmalbach T, Westlin WF.

Hepatology. 2017 Aug;66(2):324-334. doi: 10.1002/hep.29246. Epub 2017 Jul 5.

5.

Accelerating drug discovery through tight integration of expert molecular design and predictive scoring.

Abel R, Mondal S, Masse C, Greenwood J, Harriman G, Ashwell MA, Bhat S, Wester R, Frye L, Kapeller R, Friesner RA.

Curr Opin Struct Biol. 2017 Apr;43:38-44. doi: 10.1016/j.sbi.2016.10.007. Epub 2016 Nov 9. Review.

PMID:
27816785
6.

Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.

Svensson RU, Parker SJ, Eichner LJ, Kolar MJ, Wallace M, Brun SN, Lombardo PS, Van Nostrand JL, Hutchins A, Vera L, Gerken L, Greenwood J, Bhat S, Harriman G, Westlin WF, Harwood HJ Jr, Saghatelian A, Kapeller R, Metallo CM, Shaw RJ.

Nat Med. 2016 Oct;22(10):1108-1119. doi: 10.1038/nm.4181. Epub 2016 Sep 19.

7.

Ultrasound Evaluation of the Urinary Bladder in Dogs Following Cystotomy with Full Thickness Suture Placement.

Harriman GM, Popovitch C, MacLeod A.

J Am Anim Hosp Assoc. 2016 Jul-Aug;52(4):212-9. doi: 10.5326/JAAHA-MS-6381. Epub 2016 Jun 3.

PMID:
27259018
8.

Acetyl-CoA carboxylase inhibition by ND-630 reduces hepatic steatosis, improves insulin sensitivity, and modulates dyslipidemia in rats.

Harriman G, Greenwood J, Bhat S, Huang X, Wang R, Paul D, Tong L, Saha AK, Westlin WF, Kapeller R, Harwood HJ Jr.

Proc Natl Acad Sci U S A. 2016 Mar 29;113(13):E1796-805. doi: 10.1073/pnas.1520686113. Epub 2016 Mar 14.

9.

Implementation and Operational Research: CD4 Count Monitoring Frequency and Risk of CD4 Count Dropping Below 200 Cells Per Cubic Millimeter Among Stable HIV-Infected Patients in New York City, 2007-2013.

Myers JE, Xia Q, Torian LV, Irvine M, Harriman G, Sepkowitz KA, Shepard CW.

J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):e73-8. doi: 10.1097/QAI.0000000000000885.

10.

Improvements in HIV care engagement and viral load suppression following enrollment in a comprehensive HIV care coordination program.

Irvine MK, Chamberlin SA, Robbins RS, Myers JE, Braunstein SL, Mitts BJ, Harriman GA, Laraque F, Nash D.

Clin Infect Dis. 2015 Jan 15;60(2):298-310. doi: 10.1093/cid/ciu783. Epub 2014 Oct 9. Erratum in: Clin Infect Dis. 2015 Jun 15;60(12):1879. Laraque, Fabienne [added].

11.

Transitional care coordination in New York City jails: facilitating linkages to care for people with HIV returning home from Rikers Island.

Jordan AO, Cohen LR, Harriman G, Teixeira PA, Cruzado-Quinones J, Venters H.

AIDS Behav. 2013 Oct;17 Suppl 2:S212-9. doi: 10.1007/s10461-012-0352-5.

PMID:
23128979
12.

Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion.

Cao T, Wenzel SE, Faubion WA, Harriman G, Li L.

Clin Immunol. 2010 Sep;136(3):329-37. doi: 10.1016/j.clim.2010.04.014. Epub 2010 May 15.

13.

Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD).

Cao T, Soto A, Zhou W, Wang W, Eck S, Walker M, Harriman G, Li L.

Cell Immunol. 2009;258(1):65-71. doi: 10.1016/j.cellimm.2009.03.013. Epub 2009 May 1.

PMID:
19410243
14.

Measurement of mouse and human interleukin 5.

Harriman GR.

Curr Protoc Immunol. 2001 May;Chapter 6:Unit 6.5. doi: 10.1002/0471142735.im0605s14.

PMID:
18432818
15.

Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.

Harriman GC, Brewer M, Bennett R, Kuhn C, Bazin M, Larosa G, Skerker P, Cochran N, Gallant D, Baxter D, Picarella D, Jaffee B, Luly JR, Briskin MJ.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2509-12. doi: 10.1016/j.bmcl.2007.07.068. Epub 2007 Aug 21.

PMID:
18331794
16.

Small molecule antagonists of the CC chemokine receptor 4 (CCR4).

Burdi DF, Chi S, Mattia K, Harrington C, Shi Z, Chen S, Jacutin-Porte S, Bennett R, Carson K, Yin W, Kansra V, Gonzalo JA, Coyle A, Jaffee B, Ocain T, Hodge M, LaRosa G, Harriman G.

Bioorg Med Chem Lett. 2007 Jun 1;17(11):3141-5. Epub 2007 Mar 15.

PMID:
17395464
17.

Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.

Jenkins TJ, Guan B, Dai M, Li G, Lightburn TE, Huang S, Freeze BS, Burdi DF, Jacutin-Porte S, Bennett R, Chen W, Minor C, Ghosh S, Blackburn C, Gigstad KM, Jones M, Kolbeck R, Yin W, Smith S, Cardillo D, Ocain TD, Harriman GC.

J Med Chem. 2007 Feb 8;50(3):566-84.

PMID:
17266208
18.

Use of molecular imaging to quantify response to IKK-2 inhibitor treatment in murine arthritis.

Izmailova ES, Paz N, Alencar H, Chun M, Schopf L, Hepperle M, Lane JH, Harriman G, Xu Y, Ocain T, Weissleder R, Mahmood U, Healy AM, Jaffee B.

Arthritis Rheum. 2007 Jan;56(1):117-28.

19.

IKKbeta inhibition protects against bone and cartilage destruction in a rat model of rheumatoid arthritis.

Schopf L, Savinainen A, Anderson K, Kujawa J, DuPont M, Silva M, Siebert E, Chandra S, Morgan J, Gangurde P, Wen D, Lane J, Xu Y, Hepperle M, Harriman G, Ocain T, Jaffee B.

Arthritis Rheum. 2006 Oct;54(10):3163-73.

20.

Design, synthesis, and progress toward optimization of potent small molecule antagonists of CC chemokine receptor 8 (CCR8).

Ghosh S, Elder A, Guo J, Mani U, Patane M, Carson K, Ye Q, Bennett R, Chi S, Jenkins T, Guan B, Kolbeck R, Smith S, Zhang C, LaRosa G, Jaffee B, Yang H, Eddy P, Lu C, Uttamsingh V, Horlick R, Harriman G, Flynn D.

J Med Chem. 2006 May 4;49(9):2669-72.

PMID:
16640325
21.

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.

Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y.

J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001. Epub 2006 Mar 8.

PMID:
16525037
22.

Rapid TNFR1-dependent lymphocyte depletion in vivo with a selective chemical inhibitor of IKKbeta.

Nagashima K, Sasseville VG, Wen D, Bielecki A, Yang H, Simpson C, Grant E, Hepperle M, Harriman G, Jaffee B, Ocain T, Xu Y, Fraser CC.

Blood. 2006 Jun 1;107(11):4266-73. Epub 2006 Jan 26.

PMID:
16439676
23.

Synthesis of 3-amino-1,2,4-benzothiadi- azine 1,1-dioxides via a tandem aza-Wittig/heterocumulene annulation.

Blackburn C, Achab A, Elder A, Ghosh S, Guo J, Harriman G, Jones M.

J Org Chem. 2005 Nov 25;70(24):10206-9.

PMID:
16292875
24.

Immunoglobulin A-deficient mice exhibit altered T helper 1-type immune responses but retain mucosal immunity to influenza virus.

Zhang Y, Pacheco S, Acuna CL, Switzer KC, Wang Y, Gilmore X, Harriman GR, Mbawuike IN.

Immunology. 2002 Mar;105(3):286-94.

25.

IgA production without mu or delta chain expression in developing B cells.

Macpherson AJ, Lamarre A, McCoy K, Harriman GR, Odermatt B, Dougan G, Hengartner H, Zinkernagel RM.

Nat Immunol. 2001 Jul;2(7):625-31.

PMID:
11429547
26.
27.

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, Smolen JS, Weisman M, Emery P, Feldmann M, Harriman GR, Maini RN; Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.

N Engl J Med. 2000 Nov 30;343(22):1594-602.

28.

Cell adhesion antagonists: synthesis and evaluation of a novel series of phenylalanine based inhibitors.

Harriman GC, Schwender CF, Gallant D, Cochran NA, Briskin MJ.

Bioorg Med Chem Lett. 2000 Jul 17;10(14):1497-9.

PMID:
10915035
29.

Immune activation in the intestinal mucosa before the onset of colitis in Galphai2-deficient mice.

Ohman L, Franzén L, Rudolph U, Harriman GR, Hultgren Hörnquist E.

Scand J Immunol. 2000 Jul;52(1):80-90.

30.

A primitive T cell-independent mechanism of intestinal mucosal IgA responses to commensal bacteria.

Macpherson AJ, Gatto D, Sainsbury E, Harriman GR, Hengartner H, Zinkernagel RM.

Science. 2000 Jun 23;288(5474):2222-6.

31.

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.

Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P.

Lancet. 1999 Dec 4;354(9194):1932-9.

PMID:
10622295
32.

Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment.

Harriman G, Harper LK, Schaible TF.

Ann Rheum Dis. 1999 Nov;58 Suppl 1:I61-4. Review. No abstract available.

33.

Mucosal immunity to influenza without IgA: an IgA knockout mouse model.

Mbawuike IN, Pacheco S, Acuna CL, Switzer KC, Zhang Y, Harriman GR.

J Immunol. 1999 Mar 1;162(5):2530-7.

34.

Targeted deletion of the IgA constant region in mice leads to IgA deficiency with alterations in expression of other Ig isotypes.

Harriman GR, Bogue M, Rogers P, Finegold M, Pacheco S, Bradley A, Zhang Y, Mbawuike IN.

J Immunol. 1999 Mar 1;162(5):2521-9.

36.

Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice.

Blanchard TG, Czinn SJ, Redline RW, Sigmund N, Harriman G, Nedrud JG.

Cell Immunol. 1999 Jan 10;191(1):74-80.

PMID:
9918689
37.

Immunity to vaginal HSV-2 infection in immunoglobulin A knockout mice.

Parr MB, Harriman GR, Parr EL.

Immunology. 1998 Oct;95(2):208-13.

38.

G(alpha)i2-deficient mice with colitis exhibit a local increase in memory CD4+ T cells and proinflammatory Th1-type cytokines.

Hörnquist CE, Lu X, Rogers-Fani PM, Rudolph U, Shappell S, Birnbaumer L, Harriman GR.

J Immunol. 1997 Feb 1;158(3):1068-77.

PMID:
9013944
39.

Previously undiagnosed hyper-IgE syndrome in an adult with multiple systemic fungal infections.

Desai K, Huston DP, Harriman GR.

J Allergy Clin Immunol. 1996 Dec;98(6 Pt 1):1123-4. No abstract available.

PMID:
8977516
40.

Differential activation requirements of isotype-switched B cells.

Ehrhardt RO, Harriman GR, Inman JK, Lycke N, Gray B, Strober W.

Eur J Immunol. 1996 Aug;26(8):1926-34.

PMID:
8765041
41.

Synthesis, Conformational Analysis, and Biological Evaluation of Heteroaromatic Taxanes.

Georg GI, Harriman GC, Hepperle M, Clowers JS, Vander Velde DG, Himes RH.

J Org Chem. 1996 Apr 19;61(8):2664-2676.

PMID:
11667096
42.

IgA class switch in I alpha exon-deficient mice. Role of germline transcription in class switch recombination.

Harriman GR, Bradley A, Das S, Rogers-Fani P, Davis AC.

J Clin Invest. 1996 Jan 15;97(2):477-85.

43.

Gi2 alpha protein deficiency: a model of inflammatory bowel disease.

Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Bradley A, Birnbaumer L.

J Clin Immunol. 1995 Nov;15(6 Suppl):101S-105S.

PMID:
8613481
44.

Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice.

Rudolph U, Finegold MJ, Rich SS, Harriman GR, Srinivasan Y, Brabet P, Boulay G, Bradley A, Birnbaumer L.

Nat Genet. 1995 Jun;10(2):143-50.

PMID:
7663509
45.

Synthesis of a photoaffinity taxol analogue and its use in labeling tubulin.

Dasgupta D, Park H, Harriman GC, Georg GI, Himes RH.

J Med Chem. 1994 Sep 2;37(18):2976-80.

PMID:
7915327
47.

Adenosine deaminase inhibitors. Synthesis and biological evaluation of C1' and nor-C1' derivatives of (+)-erythro-9-(2(S)-hydroxy-3(R)-nonyl)adenine.

Harriman GC, Poirot AF, Abushanab E, Midgett RM, Stoeckler JD.

J Med Chem. 1992 Oct 30;35(22):4180-4.

PMID:
1433220
49.
50.

The regulation of IgA B-cell differentiation.

Strober W, Harriman GR.

Gastroenterol Clin North Am. 1991 Sep;20(3):473-94. Review.

PMID:
1917023

Supplemental Content

Loading ...
Support Center